Antiviral therapy for chronic hepatitis C: past, present, and future
- 1 January 2006
- journal article
- review article
- Published by Springer Nature in The Esophagus
- Vol. 41 (1) , 17-27
- https://doi.org/10.1007/s00535-005-1740-7
Abstract
Antiviral therapy for chronic hepatitis C has dramatically advanced since the discovery of the hepatitis C virus (HCV) in 1989 and the introduction of interferon (IFN) monotherapy in the early 1990s. The current standard therapy uses a combination of pegylated IFN and ribavirin. The duration of therapy and response to therapy are HCV genotype-specific. Genotype 1 patients require 48 weeks of the combination therapy for 50% successful viral elimination, while genotype 2 patients require 24 weeks of therapy for 80% or 90% viral elimination. Early viral kinetics after the initiation of therapy is a useful predictor of the sustained virologic response (SVR), which is formally determined at 24 weeks after completion of the treatment. For example, an early virologic response, which is determined by a 2-log reduction of HCV RNA or viral elimination at 12 weeks after the initiation of therapy, is a strong negative predictor of SVR in genotype 1 patients. In contrast, a rapid virologic response of HCV RNA-negative at 4 weeks after the initiation of therapy identifies genotype 2 “super-responders,” who may require a shorter period of therapy. Adherence to therapy is one of the most important factors for successful viral clearance. Hematopoietic growth factors such as epoetin and granulocyte-colony stimulating factor help reduce therapy-mediated cytopenia and improve patient compliance, thereby leading to better viral clearance. New types of anti-HCV agents such as HCV protease and polymerase inhibitors are needed for those patients that do not respond to combination therapy.Keywords
This publication has 69 references indexed in Scilit:
- The significance of interferon and ribavirin combination therapy followed by interferon monotherapy for patients with chronic hepatitis C in JapanHepatology Research, 2004
- Diagnosis, management, and treatment of hepatitis C†Hepatology, 2004
- EASL International Consensus Conference on Hepatitis C Paris, 26–28 February 1999Journal of Hepatology, 1999
- Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patientsJournal of Hepatology, 1999
- Response to Higher Doses of Interferon Alfa–2B in Patients With Chronic Hepatitis C: A Randomized Multicenter TrialHepatology, 1996
- Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivoHepatology, 1996
- Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: A multicenter randomized controlled trialHepatology, 1995
- Recombinant Interferon Alfa Therapy for Chronic Hepatitis CNew England Journal of Medicine, 1989
- Treatment of Chronic Hepatitis C with Recombinant Interferon AlfaNew England Journal of Medicine, 1989
- Treatment of Chronic Non-A, Non-B Hepatitis with Recombinant Human Alpha InterferonNew England Journal of Medicine, 1986